Impact of 3,4-dihydroxy-6- 18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: The referring physician's perspective

Journal of Nuclear Medicine

Volumn 53, Issue 3, 2012, Pages 393-398

  Walter, Franziska ^a   Cloughesy, Timothy ^a   Walter, Martin A ^a,b   Lai, Albert ^a   Nghiemphu, Phioanh ^a   Wagle, Naveed ^a   Fueger, Barbara ^a   Satyamurthy, Nagichettiar ^a   Phelps, Michael E ^a   Czernin, Johannes ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

18F DOPA PET CT; Amino acid transport; Glioblastoma; Glioma; Management; Outcome

Indexed keywords

3,4 DIHYDROXY 6 FLUOROPHENYLALANINE F 18; 6 FLUORODOPA F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID TRANSPORT; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT REFERRAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SURVIVAL RATE; TUMOR CLASSIFICATION; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ASTROCYTOMA; BRAIN NEOPLASMS; DIHYDROXYPHENYLALANINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OLIGODENDROGLIOMA; PATIENT CARE MANAGEMENT; PHYSICIANS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; QUESTIONNAIRES; RADIOPHARMACEUTICALS; YOUNG ADULT;

EID: 84858595468     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.095711     Document Type: Article

References (41)

1. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol.2006;2:494-503. (Pubitemid 44275725)
2. Bondy ML, Scheurer ME, Malmer B, et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer. 2008;113(7, suppl):1953-1968.
3. Gerstner ER, Sorensen AG, Jain RK, Batchelor TT. Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas. Curr Opin Neurol. 2008;21:728-735.
4. Derlon JM, Chapon F, Noel MH, et al. Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med. 2000;27:778-787. (Pubitemid 30456760)
5. Gerstner ER, Batchelor TT. Imaging and response criteria in gliomas. Curr Opin Oncol. 2010;22:598-603.
6. Chen W, Silverman DH. Advances in evaluation of primary brain tumors. Semin Nucl Med. 2008;38:240-250. (Pubitemid 351726325)
7. 18F- fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas. J Neurol Sci. 2006;246:85-94.
8. Stockhammer F, Plotkin M, Amthauer H, van Landeghem FK, Woiciechowsky C. Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in noncontrast-enhancing gliomas. J Neurooncol. 2008;88:205-210.
9. 18F-FDOPA kinetics in brain tumors. J Nucl Med. 2007;48:1651-1661.
10. 18F-FDG. J Nucl Med. 2005;46:945-952.
11. 18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714-4721.
12. Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med. 1992;33:2133-2137.
13. Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007;48:1468-1481. (Pubitemid 47397397)
14. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology.J Nucl Med. 2001;42:432-445. (Pubitemid 32207394)
15. 18F] fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40:205-212.
16. 11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med. 2000;27:542-549.
17. 18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging. 2004;31:1464-1470.
18. 11C]methionine. Eur J Nucl Med Mol Imaging. 2003;30:1561-1567.
19. Plathow C, Weber WA. Tumor cell metabolism imaging. J Nucl Med. 2008;49(suppl 2):43S-63S. (Pubitemid 351948036)
20. 18F-fluoro-L-dopa, a new tumor imaging agent: investigation of transport mechanism in vitro. J Nucl Med. 2004;45:2116-2122.
21. Kobayashi K, Ohnishi A, Promsuk J, et al. Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells. Neurosurgery. 2008;62:493-503. (Pubitemid 351489293)
22. Yee RE, Cheng DW, Huang SC, Namavari M, Satyamurthy N, Barrio JR. Blood-brain barrier and neuronal membrane transport of 6-[18F]fluoro-L-DOPA. Biochem Pharmacol. 2001;62:1409-1415. (Pubitemid 33044687)
23. 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006;47:904-911.
24. Tripathi M, Sharma R, D'Souza M, et al. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med. 2009;34:878-883.
25. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med. 2009;50:513-519.
26. 18F-L-dopa imaging of the dopamine neostriatal system in normal and clinically normal MPTP-treated rhesus monkeys. Exp Brain Res. 1989;78:69-80.
27. Pan XB, Wright TG, Leong FJ, McLaughlin RA, Declerck JM, Silverman DH. Improving influx constant and ratio estimation in FDOPA brain PET analysis for Parkinson's disease. J Nucl Med. 2005;46:1737-1744. (Pubitemid 46211598)
28. 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms. J Neurol Sci. 1996;136:169-173.
29. 18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med. 2010;51:1532-1538.
30. 18F]Fluoro-L-dopa. Int J Rad Appl Instrum [A]. 1992;43:989-996.
31. Nuyts J, Michel C, Dupont P. Maximum-likelihood expectation-maximization reconstruction of sinograms with arbitrary noise distribution using NEC-transformations. IEEE Trans Med Imaging. 2001;20:365-375. (Pubitemid 32576600)
32. Kinahan PE, Townsend DW, Beyer T, Sashin D. Attenuation correction for a combined 3D PET/CT scanner. Med Phys. 1998;25:2046-2053.
33. Olson JJ, Fadul CE, Brat DJ, Mukundan S, Ryken TC. Management of newly diagnosed glioblastoma: guidelines development, value and application. J Neurooncol. 2009;93:1-23.
34. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963-1972.
35. de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology. 2004;63:535-537. (Pubitemid 39031388)
36. Hillner BE, Siegel BA, Shields AF, et al. Impact of dedicated brain PET on intended patient management in participants of the national oncologic PET Registry. Mol Imaging Biol. 2011;13:161-165.
37. 18F] fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C] methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys. 2011;81:1049-1058.
38. 11C- methionine PET on expected management of patients with brain neoplasm. Eur J Nucl Med Mol Imaging. 2010;37:685-690.
39. Pirotte BJ, Lubansu A, Massager N, et al. Clinical impact of integrating positron emission tomography during surgery in 85 children with brain tumors. J Neurosurg Pediatr. 2010;5:486-499.
40. Seltzer MA, Yap CS, Silverman DH, et al. The impact of PET on the management of lung cancer: the referring physician's perspective. J Nucl Med. 2002;43:752-756. (Pubitemid 34663295)
41. 18F- Fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med. 2011;52:856-864.